好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Sex Differences in Proteomic Biomarkers of Incident Ischemic Stroke: the ARIC cohort study
Cerebrovascular Disease and Interventional Neurology
P5 - Poster Session 5 (11:45 AM-12:45 PM)
4-010

To identify sex-specific proteomic biomarkers associated with incident ischemic stroke (IS) in the Atherosclerosis Risk in Communities (ARIC) study.

Sex differences in IS epidemiology are well recognized. Proteomic profiling allows investigation of circulating proteins and molecular pathways that may contribute to these differences. We hypothesized that proteomic biomarkers associated with IS risk in women would differ from those in men.

ARIC participants without prior stroke at the time of proteomic profiling (Visit 2, 1990-1992) were included. Cox proportional hazards models adjusted for age, race/center, body mass index, eGFR Creatinine Cystatin, smoking, diabetes, hypertension, coronary heart disease were used to identify proteins associated with incident IS through Visit 5 (2011-2013). Proteins significant in women were then tested in men, and sex-by-protein interaction analyses were performed.

Among 11668 ARIC participants (6497 women, 5171 men), 13 proteins (among a total of 4955) were significantly associated with incident IS in women (Bonferroni threshold p<1x10-5). Among these, only CILP2, an extracellular matrix glycoprotein, was also associated with lower IS risk men (women adjusted Hazard Ratio (aHR) 0.81, 95% CI 0.73-0.9; men aHR 0.78, 0.69-0.87). Two proteins showed significant sex interaction (p<0.05/13): GPNMB, a transmembrane glycoprotein expressed in macrophages and microglia, was associated with higher IS risk in women (aHR 1.23, 1.11–1.35 vs men 0.99, 0.89-1.1), while CST6, a cysteine protease inhibitor, was associated with lower risk (aHR 0.82, 0.74-0.91 vs men 1.02, 0.91-1.16).

In ARIC participants, proteomic analysis identified both shared and sex-specific biomarkers of incident IS. CILP2 was associated with lower IS risk in both sexes, while GPNMB and CST6 showed women-specific associations, implicating inflammatory and lysosomal pathways in sex-related stroke risk. Notably, none of the statistically significant associations involved sex hormone-related proteins. These findings should be confirmed in independent cohorts to validate their generalizability and potential clinical and mechanistic relevance.

Authors/Disclosures
Sean M. Kelly, MD, PhD
PRESENTER
Dr. Kelly has nothing to disclose.
Michela Rosso, MD (NYU) Dr. Rosso has nothing to disclose.
Hubert Leo Mr. Leo has nothing to disclose.
Janina M. Herold Miss Herold has nothing to disclose.
Morgan Grams, MD, PhD The institution of Dr. Grams has received research support from NIH. The institution of Dr. Grams has received research support from NKF.
Erika Raven, PhD Dr. Raven has nothing to disclose.
Michelle C. Johansen, MD Dr. Johansen has received research support from NINDS/NIA. Dr. Johansen has received research support from American Heart Association.
Sara K. Rostanski, MD (NYU School of Medicine) Dr. Rostanski has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Individual law firms.
Scott E. Kasner, MD, FAAN (University of Pennsylvania) Dr. Kasner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. Dr. Kasner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. Dr. Kasner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Javelin. Dr. Kasner has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for UpToDate. The institution of Dr. Kasner has received research support from WL Gore. The institution of Dr. Kasner has received research support from DiaMedica. The institution of Dr. Kasner has received research support from Bayer.
Josef Coresh, MD, PhD Prof. Coresh has nothing to disclose.
Silvia Koton, PhD, RN Prof. Koton has nothing to disclose.